FMC expands debt-reduction plan via India sale; updates 2026 outlook.
Jul 29, 2026, 4:37 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The quarter shows material EBITDA/earnings weakness and a revised, still-lower growth outlook, pressuring near-term multiples. However, asset-sales and upfront licensing cash create a clearer path to deleveraging, which could limit downside and set a foundation for multiple expansion once debt burden recedes. Historical analogs show that large asset-sales can unlock value but require closing certainty and time; until those proceeds materialize and offsets to India are realized, sentiment remains cautious.
AI summary
What happened, with direct paths to the underlying reporting
FMC reported Q2 2026 revenue of $867 million, down 17% YoY (ex-India down 20%), with a GAAP net loss of $187 million and adjusted EBITDA of $153 million. The company reaffirmed a 2026 outlook of $3.50–$3.70 billion in revenue and $620–$680 million in EBITDA, while guiding free cash flow of $75–$225 million. Management outlined a roughly $1 billion debt-paydown plan funded by India asset sale ($252m), a Rimisoxafen upfront ($200m), a Newark leaseback ($114m), and a Tessenderlo equity investment ($400m).
Q2 2026 revenue $867m; down 17% YoY (ex-India $841m, down 20%).
GAAP net loss $187m; Adjusted EBITDA $153m, down 26%.
Debt-paydown plan targets ~$1B; proceeds from India sale, Newark leaseback, Tessenderlo investment.
India held-for-sale sale progressing; Rimisoxafen upfront $200m; licensing strengthens cash flow.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
